Periodic Reporting for period 2 - BRONCHOTHELIN (The first-in-class disease-modifying drug for chronic airway disorders)

EpiEndo Pharmaceuticals is a drug development company focused on developing novel drugs that target epithelial differentiation and enhance regeneration and barrier function. In contrast to the prevailing anti-inflammatory approach to respiratory drug discovery, EpiEndo has...